Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

The latest in immuno research, from the discovery & development of cell & antibody therapies through to omics-based approaches and clinical case studies

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Translational & Preclinical Development

Crown Bioscience: Discover the Infinite Power of Partnership

We are Crown Bioscience and this is where Innovation and Quality Transforms Scientific Discovery
Read More
Autoimmunity & Immunology

Novel Targets and Studies in Immunology and Autoimmunity: Antigen-Specific Immunotherapy and Therapeutic Chaperones

Insights on antigen-specific immunotherapy and the immunomodulatory functions of therapeutic chaperones at Immuno UK 2022.
Read More
Translational & Preclinical Development

Evaxion Biotech Announce New Source of Immunotherapeutic Targets via AI Platform

ERVs have been strongly associated with overall survival in cancer patients. Evaxion hopes they can act as therapeutic targets for non-responsive immunotherapy patients.
Read More
Biomarkers in Immuno-Oncology

Improving Patient Response Through Effective Biomarker Development

Oxford Global's panel discussion brings together expert scientists in the field of immunology and biomarker development.
Read More
Therapeutic Modalities

Targeting oxMIF To Develop Novel Biotherapeutics

An interview with Michael Thiele, Chief Scientific Officer, OncoOne Research & Development GmbH.
Read More
Therapeutic Modalities

Chipscreen Licences Eucure Biopharma's Keytruda Competitor for Greater China

The investigational bispecific antibody has demonstrated favourable efficacy and safety in preclinical in vivo testing.
Read More
Translational & Preclinical Development

Sensei Bio Presents Preclinical Data for Novel Antibody Therapeutic for Solid Tumours

Immuno-oncology company Sensei Bio gave a presentation which outlined convincing preclinical data for their novel antibody therapeutic.
Read More
Therapeutic Modalities

Therapy In the Spotlight: CAR T Cell Therapy—Significant Approvals and Regulatory Concerns

What are the regulatory considerations for CAR T cell therapy, and what's next for the approach?
Read More
Autoimmunity & Immunology

Exploring the Role of IFNa in Autoimmunity & Infection

On-Demand Webinar featuring Dr Darragh Duffy, LabEx Coordinator at Institut Pasteur
Read More
Therapeutic Modalities

Novel TNF Superfamily Antagonists for Cancer & Autoimmunity

An interview with Russell LaMontagne, Co-Founder and Chief Executive Officer, Boston Immune Technologies and Therapeutics
Read More
Translational & Preclinical Development

AI-Guided Personalised Cancer Vaccine Designated Fast Track by FDA

Evaxion Biotech uses AI to personalise cancer vaccines for patients’ specific tumours.
Read More
Translational & Preclinical Development

Teon Tx and MSD Partner in Oral IO Clinical Trial

Teon Tx and MSD will partner to study a combination of a new immune-modifier and existing anti-PD-1 immune checkpoint inhibitor.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things immuno